Keynote Discussion

ESH eLearning, Lucio Luzzatto, 336794

KEYNOTE PRESENTATION: PNH as paradigm of the mutability of bone marrow failure

ESH eLearning, Lucio Luzzatto, 336793

Discussion

ESH eLearning, Faculty / Presenters, 336792

Selected brief oral communication: Single Cell eQTL Mapping Identifies Cell-Type Specific Control of Autoimmune Disease

ESH eLearning, Kirsten Fairfax, 336791

Modern diagnosis of aplastic anaemia and PNH

ESH eLearning, Austin Kulasekararaj, 336790

Pathophysiology of PNH

ESH eLearning, Rosario Notaro, 336789

Pathophysiology of immune aplastic anaemia

ESH eLearning, Neal Young, 336788

SATELLITE SYMPOSIUM: Beyond current endpoints: a patient-centric approach to PNH treatment

ESH eLearning, Régis Peffault de, 336787

Discussion

ESH eLearning, Faculty / Presenters, 336786

Selected brief oral communication: Natural History and Outcomes Depending on Organ System Involvement in Patients with Clinically-Relevant Short Telomeres

ESH eLearning, Abhishek Mangaonkar, 336785

Dyskeratosis congenita and related haematological diseases

ESH eLearning, Inderjeet Dokal, 336784

Discussion

ESH eLearning, Faculty / Presenters, 336783

Management of ribosomopathies

ESH eLearning, Yigal Dror, 336782

Diamond-Blackfan anaemia (DBA), ribosomes and haematopoiesis

ESH eLearning, Vijay Sankaran, 336781

Discussion

ESH eLearning, Faculty / Presenters, 336780

Classical and new treatment of Fanconi anaemia

ESH eLearning, Carlo Dufour, 336779

Selected brief oral communication: Immunologic Basis to Poor Graft Function Post Allogeneic Transplantation

ESH eLearning, Ashvind Prabahran, 336778

Panel discussion

ESH eLearning, Faculty / Presenters, 314113

Amyloidosis

ESH eLearning, Giampaolo Merlini, 314112

POEMS

ESH eLearning, Arnaud Jaccard, 314111

Waldenstrom’s disease

ESH eLearning, Jorge Castillo, 314110

Panel discussion

ESH eLearning, Faculty / Presenters, 314109

Bureaucracy is strangling clinical research

ESH eLearning, Steven Le Gouill, 314108

iStopMM-a nationwide screening for MGUS and myeloma and early treatment of smoldering myeloma

ESH eLearning, SIGURDUR KRISTINSSON, 314107

How to sequence in 1st and 2nd relapse?

ESH eLearning, Meletios Dimopoulos, 314098

Beyond 2nd relapse

ESH eLearning, Saad Usmani, 314099

Panel discussion

ESH eLearning, Faculty / Presenters, 314097

Update of CARTITUDE-1: A Phase 1b/2 Study of JNJ-68284528 (JNJ-4528), a B-Cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) Cell therapy, in relapsed/refractory multiple myeloma (MM)

ESH eLearning, Deepu Madduri, 314101

Panel discussion

ESH eLearning, Faculty / Presenters, 314102

Novel targeted therapies (not immune)

ESH eLearning, Shaji Kumar, 314103

Novel immunotherapies (part 1)

ESH eLearning, Hermann Einsele, 314104

Novel immunotherapies (part 2)

ESH eLearning, Sagar Lonial, 314105

Panel discussion

ESH eLearning, Faculty / Presenters, 314106

How MRD assessment will impact clinical management

ESH eLearning, Noemi Puig, 314096

MRD and immune profiling (differences in terms of response)

ESH eLearning, Bruno Paiva, 314095

MRD and imaging

ESH eLearning, Elena Zamagni, 314094

Overview immune therapies?

ESH eLearning, Noopur Raje, 314100

Panel discussion

ESH eLearning, Faculty / Presenters, 314093

Maintenance therapy

ESH eLearning, Graham Jackson, 314092

US point of view on new trials (including explanation of why HSCT is not proposed frontline)

ESH eLearning, PAUL RICHARDSON, 314091

Panel discussion

ESH eLearning, Faculty / Presenters, 314090

Fit vs frail: The point of view of North America

ESH eLearning, Hira Mian, 314089

Fit vs Frail: the European point of view

ESH eLearning, Sonja Zweegman, 314088

Overview phase 3 trials and newly approved treatments

ESH eLearning, Xavier Leleu, 314087

Clinical trials

ESH eLearning, María-Victoria Mateos, 314081

Panel discussion

ESH eLearning, Faculty / Presenters, 314082

High-risk smoldering : what is the exact definition 

ESH eLearning, Irene Ghobrial, 314080

Panel discussion

ESH eLearning, Faculty / Presenters, 314086

Frailty assessment at diagnosis

ESH eLearning, Alessandra Larocca, 314085

Genetics and risk assessment

ESH eLearning, Hervé Avet-Loiseau, 314084

Diagnostic criteria and initial workup

ESH eLearning, Shaji Kumar, 314083

Selected Abstract: High Body Mass Index (BMI) and Treatment Responses in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving First-Line Dasatinib or Imatinib: Exploratory Post Hoc Analysis of the Phase 3 DASISION Study

ESH eLearning, Massimo Breccia, 336776

Selected Abstract: Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia

ESH eLearning, James Januzzi, 336775

" CML management in war and peace: lessons that shaped future approaches

ESH eLearning, Sabira Kurtovic, 336773

Voting and Discussion

ESH eLearning, Faculty / Presenters, 336771

For

ESH eLearning, Giuseppe Saglio, 336770

Discussion

ESH eLearning, Faculty / Presenters, 336768

Computational Pathology: Towards Precision Medicine

ESH eLearning, Andrew Janowczyk, 336767

Discussion

ESH eLearning, Giovanni Martinelli, 336766

Human evolutionary genomic medicine

ESH eLearning, Melissa Ilardo, 336765

Discussion

ESH eLearning, Faculty / Presenters, 336764

Selected Abstract: Best Duration of Deep Molecular Remission to Achieve Therapy-Free Remission in Chronic Myeloid Leukaemia

ESH eLearning, Robert Peter GALE, 336763

Selected Abstract: Chronic Myeloid Leukemia Patients’ Concerns during Phase I of the Treatment-Free Remission Journey: Considerations Between Patients and Doctors in the Different CML Advocates Network Regions

ESH eLearning, Giora Sharf, 336762

Discussion

ESH eLearning, Delphine Agnes, 336761

Keynote presentation Successful TFR in CML: is it predictable?

ESH eLearning, Yong Agnes, 336760

Discussion

ESH eLearning, Faculty / Presenters, 336759

Selected Abstract: Efficacy and Safety of Pioglitazone in a Phase II Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia Patients

ESH eLearning, Katia Pagnano, 336758

Selected Abstract: High Level of Successful TKI Discontinuation Outside Clinical Trials - a Population-Based Study from the Swedish CML Registry

ESH eLearning, Johan Richter, 336757

High dimensional single-cell analysis to predict TFR at the time of CML diagnosis

ESH eLearning, Vaidehi Krishnan, 336755

Discussion

ESH eLearning, Faculty / Presenters, 336753

Selected Abstract: Radotinib Treatment for Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to or Intolerant of BCR-ABL1 Tyrosine-Kinase Inhibitors: 60-Month Follow-up of a Phase 2 Study

ESH eLearning, Sung-Hyun Kim, 336752

Selected Abstract: Activity of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) in CML Patients Failing TKI Therapies Including Ponatinib

ESH eLearning, Jorge Cortes, 336751

Discussion

ESH eLearning, Giantonio Rosti, 336750

Keynote presentation Citius, Altius, Fortius ?

ESH eLearning, Andreas Hochhaus, 336749

Discussion

ESH eLearning, Faculty / Presenters, 336748

Investigating secretome and sheddome composition with proteomic approaches

ESH eLearning, Oliver Schilling, 336747

MS-proteomics to uncover the complexity and function of the cell secretome

ESH eLearning, Sara Zanivan, 336746

Discussion

ESH eLearning, Faculty / Presenters, 336745

Bispecific antibodies in leukemia

ESH eLearning, Roland B. Walter, 336744

Checkpoint inhibitors

ESH eLearning, Justin Kline, 336743

Leukemia vaccines

ESH eLearning, David Scheinberg, 336741

Discussion

ESH eLearning, Faculty / Presenters, 336740

Selected Abstract: Discovery of Novel CIP2A Variant (NOCIVA) and its Clinical Association with Myeloid Leukemias

ESH eLearning, Eleonora Mäkelä, 336739

Selected Abstract: UNX1 Mutations in Blast Phase Chronic Myeloid Leukemi

ESH eLearning, Shady Adnan Awad, 336738

Keynote presentation CRISPR predictions about relaps in CML

ESH eLearning, Daniel Bolon, 336736

Discussion

ESH eLearning, Rob Welner, 336735

Special Lecture The seed and the soil - the leukemia stem cell in its niche and the quest for cure

ESH eLearning, Ravi Bhatia, 336734

Discussion

ESH eLearning, Daniela Krause, 336732

Keynote presentation Regulation of hematopoietic stem and progenitor cells by the bonemarrow microenvironment

ESH eLearning, Ralf Adams, 336731

Discussion

ESH eLearning, Faculty / Presenters, 336730

Selected Abstract: Molecular Status 36 Months after TKI-Discontinuatíon in CML Is Highly Predictive for Later Loss of MMR - a Report from after−SKI.

ESH eLearning, Johan Richter, 336729

Selected Abstract: Interim Analysis from the Optic Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib

ESH eLearning, Jorge Cortes, 336728

Selected Abstract: Tgfβr - SMAD3 Signaling Protects CML and Other Myeloid Malignancies from Synthetic Lethality Triggered By PARP Inhibitor in Bone Marrow Microenvironment

ESH eLearning, Bac Viet Le, 336727

Selected Abstract: Targeted RNA-Based Gene Sequencing Identifies Mutated Blood Cancer-Linked Genes at Diagnosis of CML That Are Associated with Treatment Failure

ESH eLearning, Susan Branford, 336726

Discussion

ESH eLearning, Faculty / Presenters, 312793

Standard and new options for T-ALL

ESH eLearning, David Teachey, 312792

Panel discussion

ESH eLearning, Faculty / Presenters, 312791

Case-based lecture: Immune check-point inhibitors in acute leukaemia

ESH eLearning, Naval Daver, 312790

Case-based lecture: CAR T-cells for precursor B-cell ALL

ESH eLearning, Françoise Méchinaud, 312789

Case-based lecture: Use of blinatumomab in ALL

ESH eLearning, Anita Rijneveld, 312788